Targeting the microenvironment in solid tumors.
暂无分享,去创建一个
Giuseppe Curigliano | Paolo D'Amico | Bruno Achutti Duso | F. Orsi | G. Curigliano | G. Viale | B. Duso | D. Trapani | C. Belli | P. D’Amico | Franco Orsi | Carmen Belli | Dario Trapani | Giulia Viale | Paolo Della Vigna | P. Della Vigna
[1] J. Berzofsky,et al. Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma , 2014, PloS one.
[2] M. van de Rijn,et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. , 2015, The New England journal of medicine.
[3] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[4] Xian Zhou,et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Desai,et al. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[6] S. Rafii,et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.
[7] I. Macreadie,et al. Direct integrin αvβ6-ERK binding: implications for tumour growth , 2002, Oncogene.
[8] Geoffrey C Gurtner,et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.
[9] D. Heitjan,et al. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients , 2013, Oncoimmunology.
[10] J. Wolchok,et al. Targeting T Cell Co-receptors for Cancer Therapy. , 2016, Immunity.
[11] E. Stanley,et al. Colony-stimulating factor-1 in immunity and inflammation. , 2006, Current opinion in immunology.
[12] R. Hoffman,et al. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. , 2013, Blood.
[13] C. Drake,et al. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.
[14] Wenjun Guo,et al. Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.
[15] E. Wherry,et al. Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.
[16] R. Ramlau,et al. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Y. Maru,et al. Imbalance of Clara cell-mediated homeostatic inflammation is involved in lung metastasis , 2011, Oncogene.
[18] Hua Yu,et al. Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.
[19] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[20] Richard O. Hynes,et al. The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.
[21] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[22] S. Ugel,et al. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. , 2015, The Journal of clinical investigation.
[23] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[24] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[25] Mette M. Rosenkilde,et al. Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.
[26] Hong Zhang,et al. Cellular response to hypoxia involves signaling via Smad proteins. , 2003, Blood.
[27] C. Piccirillo,et al. Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives , 2011, Clinical Cancer Research.
[28] Apurva A Desai,et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[30] J. Allison,et al. Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.
[31] P. V. van Diest,et al. Hypoxia‐inducible factor‐1α is associated with angiogenesis, and expression of bFGF, PDGF‐BB, and EGFR in invasive breast cancer , 2005 .
[32] Z. Werb,et al. Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells , 1997, The Journal of cell biology.
[33] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[34] J. Riezu-Boj,et al. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. , 2011, Cancer research.
[35] E. Voest,et al. Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. , 2010, Neoplasia.
[36] E. Hay,et al. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. , 2005, Cells, tissues, organs.
[37] J. Allison,et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.
[38] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Douglas Hanahan,et al. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .
[40] Richard O Hynes,et al. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. , 2012, Cancer discovery.
[41] J. Hamilton,et al. Control of macrophage lineage populations by CSF‐1 receptor and GM‐CSF in homeostasis and inflammation , 2012, Immunology and cell biology.
[42] A. Agarwal,et al. PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.
[43] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[44] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[45] Alison Martin,et al. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. , 2015, Future oncology.
[46] R. Greil,et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[47] Y Quijano,et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer , 2013, British Journal of Cancer.
[48] A. Harris,et al. A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer , 2004, Clinical Cancer Research.
[49] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[50] K. Hoang-Xuan,et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[51] T. Bekaii-Saab,et al. Disrupting Cytokine Signaling in Pancreatic Cancer: A Phase I/II Study of Etanercept in Combination With Gemcitabine in Patients With Advanced Disease , 2013, Pancreas.
[52] Kristian Pietras,et al. High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.
[53] F. Finkernagel,et al. The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization , 2016, Oncotarget.
[54] I. Pinchuk,et al. PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity. , 2008, Gastroenterology.
[55] S. H. van der Burg,et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] E. Perez,et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] H. Kaufman,et al. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. , 2010, Future oncology.
[58] I. Kerr,et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon , 1990, Cell.
[59] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[60] A. Heitger. Regulation of expression and function of IDO in human dendritic cells. , 2011, Current medicinal chemistry.
[61] P. Carmeliet. Angiogenesis in health and disease , 2003, Nature Medicine.
[62] G. Hu,et al. New horizons in tumor microenvironment biology: challenges and opportunities , 2015, BMC Medicine.
[63] Dennis C. Sgroi,et al. Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.
[64] Nels C. Elde,et al. Protein kinase R reveals an evolutionary model for defeating viral mimicry , 2008, Nature.
[65] E. Small,et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] Ana C Anderson,et al. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.
[67] Yuquan Wei,et al. Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature , 2012, PloS one.
[68] D. Munn,et al. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.
[69] Xin Huang,et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] G. Coukos,et al. The parallel lives of angiogenesis and immunosuppression: cancer and other tales , 2011, Nature Reviews Immunology.
[71] Antonio Polley,et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.
[72] E. Van Cutsem,et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] Li Yang,et al. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. , 2010, Trends in immunology.
[74] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[75] Naotoshi Sugimoto,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[76] J. Wolchok,et al. Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy , 2014, Science Translational Medicine.
[77] J. Soria,et al. Annals of Oncology , 2022 .
[78] C. Carman,et al. Structural basis of integrin regulation and signaling. , 2007, Annual review of immunology.
[79] Raghu Kalluri,et al. Fibroblasts in cancer , 2006, Nature Reviews Cancer.
[80] J. Blay,et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.
[81] M. Ashcroft,et al. Hypoxia‐inducible factor‐1 and oncogenic signalling , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.
[82] S. Steinberg,et al. Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors , 2011, Clinical Cancer Research.
[83] C. Heldin,et al. Non-Smad TGF-β signals , 2005, Journal of Cell Science.
[84] E. Van Cutsem,et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. , 2015, The Lancet. Oncology.
[85] M. Karin,et al. Signal transduction by tumor necrosis factor and its relatives. , 2001, Trends in cell biology.
[86] B. Aggarwal,et al. Role of nuclear factor-κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents , 2011, Experimental biology and medicine.
[87] G. Ahn,et al. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature , 2009, Angiogenesis.
[88] S. Rafii,et al. The bone marrow vascular niche: home of HSC differentiation and mobilization. , 2005, Physiology.
[89] A. Tolcher,et al. Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study , 2008, Clinical Cancer Research.
[90] Beverly A. Teicher,et al. Transforming Growth Factor-β and the Immune Response to Malignant Disease , 2007, Clinical Cancer Research.
[91] G. Semenza,et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[92] P. Allavena,et al. Cancer-related inflammation , 2008, Nature.
[93] Dana M. Brantley-Sieders,et al. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. , 2009, Cancer research.
[94] Hae-Yun Jung,et al. Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis , 2014, Clinical Cancer Research.
[95] J. Larkin,et al. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma , 2010, British Journal of Cancer.
[96] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[97] Andreas Sashegyi,et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.
[98] J. Blay,et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. , 2015, The Lancet. Oncology.
[99] M. Gore,et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[101] F. Richards. Molecular pathology of von Hippel–Lindau disease and the VHL tumour suppressor gene , 2001, Expert Reviews in Molecular Medicine.
[102] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[103] B. Fingleton,et al. Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.
[104] Z. Werb,et al. Extracellular matrix degradation and remodeling in development and disease. , 2011, Cold Spring Harbor perspectives in biology.
[105] D. Lyden,et al. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. , 2011, Seminars in cancer biology.
[106] A B West,et al. Myofibroblasts: paracrine cells important in health and disease. , 2000, Transactions of the American Clinical and Climatological Association.
[107] G. Scagliotti,et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] Alberto Mantovani,et al. Inflammation and cancer: back to Virchow? , 2001, The Lancet.
[109] A. Ribas,et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) , 2017, The Lancet.
[110] C. Nelson,et al. New insights into the regulation of epithelial-mesenchymal transition and tissue fibrosis. , 2012, International review of cell and molecular biology.
[111] B. Hinz,et al. Myofibroblasts and mechano-regulation of connective tissue remodelling , 2002, Nature Reviews Molecular Cell Biology.
[112] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.
[113] Dong Eun Kim,et al. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation , 2015, Nature Cell Biology.
[114] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[115] R. Salazar,et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.